News

Scientists have taken a step closer to an effective vaccine against Strangles, a scourge of the equine world that causes considerable pain and suffering to horses and ponies worldwide.

Novel screening method shows promise for finding new targets for already-approved drugs such as kinase inhibitors.

Researchers demonstrate the addition of widely available antioxidants to the current standard-of-care prevents vision loss in an animal model of a rare genetic disease.

Life sciences professionals and business development dealmakers from all walks of industry, academia and government have a new interchange at SLAS2018 – SLAS Ignite, a series of programs that foster scientific innovation through collaboration, debuts at the 2018 SLAS International Conference and Exhibition.

A newly published article explores the development and validation of a new enzyme-linked immunosorbent assay (ELISA) with high sensitivity and selectivity for bioanalysis of bevacizumab (BEV), a monoclonal antibody used for immunotherapy of different types of cancer.

University of Toronto researchers have developed a new technology for creating more durable disease-fighting molecules which could lead to drugs with longer-lasting effects.

Injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a study by researchers at the Stanford University School of Medicine.

Until now the use of adenoviruses in tumor therapy has been very limited. They lack the ability to infect cancer cells and therefore cannot inject the genetic blueprints for the therapeutic molecules to fight the disease. Researchers have now succeeded in rebuilding the viruses so that they effectively recognize and infect tumor cells.

James P. Allison was the first to demonstrate that immunotherapy can treat cancer effectively, initiating an approach that "has provided clinical benefit to many cancer patients" and "stimulated the development of a new class of drugs employing the immune system to fight cancer."

Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has announced the expansion of its international commercial operations.